Daclizumab Phase II Trial in Relapsing and Remitting Multiple Sclerosis
Neurol 69:785-789, Rose,J.W.,et al, 2007
MR Imaging of Human Herpesvirus-6-Associated Encephalitis in 4 Patients with Anterograde Amnesia after Allogeneic Hematopoietic Stem-Cell Transplantation
AJNR 27:887-891, Gorniak,R.J.T.,et al, 2006
Statin-Associated Myasthenia Gravis
Medicine 85:82-85, Purvin,V.,et al, 2006
Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005
Memantine Treatment in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil, A Randomized Controlled Trial
JAMA 291:317-324, Tariot,P.N.,et al, 2004
Management of Myasthenia Gravis
Semin Neurol 24:41-48, Saperstein,D.S. &Barohn,R.J., 2004
Tolerability of Memantine in Combination with Cholinesterase Inhibitors in Dementia Therapy
Int Clin Psychopharm 18:81-85, Hartmann,S.& Mobius, H.J., 2003
Cerebral Vasoconstriction and Stroke After Use of Serotonergic Drugs
Neurol 58:130-133, Singhal,A.B.,et al, 2002
Human Herpesvirus 6 Limbic Encephalitis After Stem Cell Transplantation
Ann Neurol 50:612-619, Wainwright,M.S.,et al, 2001
Serotonin Sydrome
Medicine 79:201-209, Mason,P.J. et al, 2000
Amelioration of Flulike Symptoms at the Onset of Interferon B-1b Therapy in Multiple Sclerosis by Low-Dose Oral Steriods is Related to a Decrease in Interleukin-6 Induction
Ann Neurol 44:682-685, Martinez-Caceres,E.M.,et al, 1998
Cytokine Elevations in Infants with Bacterial and Aseptic Meningitis
J Pediatr 126:872-876, Dulkerian,S.J.,et al, 1995
The Impact of New Pharmaceutical Agents on the Cost of Neurologic Care
Neurol 45:569-572, Gunderson,C.H., 1995
Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995
The Use of Sumatriptan in Patients with Monoamine Oxidase Inhibitors
Neurol 45:1039-1040, Diamond,S., 1995
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Comparisons of Therapeutic Effects of Levodopa
Levodopa & Selegiline, & Bromocriptine in Pts with Early, Mild Parkinson's, Parkinson's Res Grp in U, , BMJ 372,1993., 1993
Pergolide and Selegiline for Parkinson's Disease
The Medical Letter, 31:81-841989., , 1989
Pyridoxine Deficiency & Peripheral Neuropathy Associated with Long-Term Phenelzine Therapy
Am J Med 75:887-888, Heller,C.A.,et al, 1983
Meige Disease:Striatal Dopaminergic Preponderance
Neurol 29:1126-1130, Tolosa,E.S.,et al, 1979
Considerations in the Management of Parkinsonism
Neurol 28:5, Fahn,S.,et al, 1978
Drug Therapy of Tardive Dyskinesia
NEJM 296:257, Kobayashi,R.M., 1977
Asundexian for Secondary Stroke Prevention
NEJM 394:1467-1479, 1540, Sharm,M.,et al, 2026
A 28-Year-Old Man with Seizures and Thalamic Lesions
Neurol 106:e218065, Santos-Rojo,A.B.,et al, 2026
Autoimmune Encephalitis as Treatment-Responsive Cause of Rapidly Progressive Dementia
Neurol 106:e214933, van Steenhoven,R.W.,et al, 2026
Creutzfeldt-Jakob-Like Presentation in Anti-AMPAR Encephalitis
Ann Neurol 99:1466-1467, Durbano,K.et al, 2026
Safety and Outcomes of Dibigatran Reversal with Idarucizumab Before IV Thrombolysis in Patients with Acute Ischemic Stroke
Neurol 106:e218012, Saflund,M.,et al, 2026
Peripheral Neuropathy, A Review
JAMA 335:255-266, Mauermann,M.L. & Staff,N.P., 2026
High-Grade Gliomas with Autoimmune Encephalitis-Like Presentation: Case Report and Systematic Review of the Literature
Neurological Sci 46:3559-3572, Creda,G.S.et al, 2025
Anti-NMDAR Encephalitis Triggered by EBV and HSV-1
Medicine 104:28, Zhan,X.,et al, 2025
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Idiopathic Intracranial Hypertension
NEJM 393:1409-1414, Horton,J.C., 2025
A 66-Year-Old Man with Chronic Orthostatic Hypotension
Neurol 105:e214294, Lenka,A. & Vernino,S, 2025
Myelin Oligodendrocyte Glycoprotein Antibody - Associated Cerebral Cortical Encephalitis: A Case Report Highlighting Diagnostic Challenges and Therapeutic Implications
Front Immunol 16:1619807, Liu,M. & Li, D., 2025
A 60-Year-Old Man with Rapidly Progressive Left Hemibody Weakness and Vision Loss
Neurol 105: e213869, Rock,M.,et al, 2025
Collaboration on the Optimal Timing of Anticoagulation after Ischaemic Stroke and Atrial Fibrillation:A Systematic Review and Prospective Individual Participant Data Meta-Analysis of Randomised Controlled Trials (CATALYST)
Lancet 406:43-51, Dehbi,K-M.,et al, 2025
Clinicopathologic conference, Malignant Mixed Germ-Cell Tumor and Anti-NMDA Receptor Encephalitis
NEJM 303:488-496, Case 22-2025, 2025
A 72-Year-Old Man with Progressive Pan-Dysautonomia
Neurol 105:e213994, Zelikovich,A.S.,et al, 2025
A Woman with Subacute Progression of Distal Upper Extremity Weakness
Neurol 105:e214212, Zhao,A.J.,et al, 2025
Calcitonin Gene-Related Peptide-Targeted Therapy in Migraine: Current Role and Future Perspectives
Lancet 405:1014-1026, Versijpt,J.,et al, 2025
Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025
Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025
Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice
Neurol 104:e213498, Zara,P.,et al, 2025
Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025
Upadacitinib - An Up-and-Comer for Treatment of Giant-Cell Arteritis
NEJM 392:2062-2064, Koster,M.J. & Warrington,K.J., 2025
A 69-Year-Old Woman with Ophthalmoplegia
Neurol 104:e213763, Yu, H & Frey, J, 2025
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
NEJM 392:2309-2320, Nowak,R.J.,et al, 2025
Myasthenia Gravis - Redemption for B-Cell Depletion
NEJM 392:2382-2384, Wolfe,G.I. & Shelly,S., 2025
Efficacy and Safety of Selimetinib in Adults with Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas (KOMET): A Multcentre, International, Randomised Placebo-Controlled, Parallel, Double-Blind, Phase 3 Study
Lancet 405:2217-2230, Chen,A.P.,et al, 2025